Have a feature idea you'd love to see implemented?
Let us know!
CRBP Corbus Pharmaceuticals Holdings Inc
Price (delayed)
$19.91
Market cap
$239.79M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.79
Enterprise value
$230.23M
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company's lead product candidate, lenabasum, is
Highlights
The quick ratio has soared by 171% YoY and by 32% QoQ
Corbus Pharmaceuticals Holdings's EPS has increased by 47% YoY and by 17% QoQ
Corbus Pharmaceuticals Holdings's net income has increased by 24% YoY but it has decreased by 3.6% from the previous quarter
Key stats
What are the main financial stats of CRBP
Market
Valuations
Earnings
Shares outstanding
12.04M
Market cap
$239.79M
Enterprise value
$230.23M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.69
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$32.67M
EBITDA
-$32.07M
Free cash flow
-$30.1M
Per share
Balance sheet
Liquidity
EPS
-$5.79
Free cash flow per share
-$2.72
Book value per share
$11.75
Revenue per share
$0
TBVPS
$13.75
Total assets
$151.98M
Total liabilities
$26.44M
Debt
$14.8M
Equity
$125.54M
Working capital
$124.33M
Debt to equity
0.12
Current ratio
6.18
Quick ratio
6.16
Net debt/EBITDA
0.3
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-40.9%
Return on equity
-64.8%
Return on invested capital
-54.6%
Return on capital employed
-25.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRBP stock price
How has the Corbus Pharmaceuticals Holdings stock price performed over time
Intraday
-0.99%
1 week
-7.35%
1 month
-64.25%
1 year
217.54%
YTD
229.64%
QTD
-3.49%
Financial performance
How have Corbus Pharmaceuticals Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$40.2M
Net income
-$34.97M
Gross margin
N/A
Net margin
N/A
Corbus Pharmaceuticals Holdings's net income has increased by 24% YoY but it has decreased by 3.6% from the previous quarter
The operating income is up by 10% year-on-year but it is down by 7% since the previous quarter
Growth
What is Corbus Pharmaceuticals Holdings's growth rate over time
Valuation
What is Corbus Pharmaceuticals Holdings stock price valuation
P/E
N/A
P/B
1.69
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Corbus Pharmaceuticals Holdings's EPS has increased by 47% YoY and by 17% QoQ
CRBP's P/B is 86% below its 5-year quarterly average of 11.9
The company's equity rose by 29% QoQ
Efficiency
How efficient is Corbus Pharmaceuticals Holdings business performance
The ROE has soared by 65% YoY and by 52% QoQ
The ROA has increased by 48% YoY and by 29% from the previous quarter
CRBP's return on invested capital is up by 29% year-on-year and by 29% since the previous quarter
Dividends
What is CRBP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRBP.
Financial health
How did Corbus Pharmaceuticals Holdings financials performed over time
The quick ratio has soared by 171% YoY and by 32% QoQ
Corbus Pharmaceuticals Holdings's current ratio has surged by 164% YoY and by 32% QoQ
CRBP's debt is 88% smaller than its equity
CRBP's debt to equity has dropped by 95% year-on-year and by 33% since the previous quarter
CRBP's debt is down by 38% year-on-year and by 14% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.